United Therapeutics Unveils Data on Pulmonary Hypertension, Lung Transplant Tech at ISHLT 2026
Event summary
- United Therapeutics presents 11 new data sets at ISHLT 2026, spanning pulmonary hypertension treatment, lung donor expansion, and xenotransplantation.
- ARTISAN and PHINDER studies suggest early detection and intervention improve outcomes for pulmonary hypertension patients.
- Machine learning applications in ex-vivo lung perfusion (EVLP) aim to predict donor lung acceptance in real-time.
- Xenotransplantation research includes genetically modified porcine hearts and prolonged pig-to-baboon lung xenograft survival.
The big picture
United Therapeutics' data presentations at ISHLT 2026 highlight its dual focus on improving pulmonary hypertension treatment and expanding the supply of transplantable organs. The company's advancements in machine learning for EVLP and xenotransplantation reflect broader industry trends toward AI-driven diagnostics and bioengineered organ solutions. Success in these areas could position United Therapeutics as a leader in addressing critical gaps in lung disease management and transplantation.
What we're watching
- Clinical Validation
- Whether ARTISAN and PHINDER findings will reshape pulmonary hypertension management.
- Organ Supply
- The pace at which xenotransplantation and EVLP technologies can address transplantable organ shortages.
- Regulatory Pathways
- How machine learning applications in EVLP will navigate regulatory approvals for real-time clinical use.
Related topics